文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
Joseph Burgents
发表
610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
N. Agarwal, C. Corcoran, O. Sartor, 2020, Annals of Oncology.